Moderna, Inc. vs Regeneron Pharmaceuticals, Inc.: Strategic Comparison

This in-depth comparison examines Moderna, Inc. and Regeneron Pharmaceuticals, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Moderna, Inc. on its own, evaluating Regeneron Pharmaceuticals, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Moderna, Inc. and Regeneron Pharmaceuticals, Inc. is widest.

On the headline numbers, Moderna, Inc. reports annual revenue of $1.9B against $14.3B for Regeneron Pharmaceuticals, Inc., while their respective market capitalizations stand at $23.6B and $66.6B. Moderna, Inc. is headquartered in United States and Regeneron Pharmaceuticals, Inc. operates from United States, and those different home markets shape how each company competes.

Moderna, Inc.: Moderna, Inc. is a public company listed on NASDAQ under ticker MRNA. Moderna makes money from product sales of mRNA vaccines and from collaboration, grant, and licensing revenue tied to its mRNA platform and pipeline.

Regeneron Pharmaceuticals, Inc.: Regeneron sits in biotechnology, where scientific productivity, regulatory execution, reimbursement, and patent life determine long-term economics.

Moderna, Inc. and Regeneron Pharmaceuticals, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Moderna, Inc. and Regeneron Pharmaceuticals, Inc..

Moderna, Inc. business model: Moderna makes money from product sales of mRNA vaccines and from collaboration, grant, and licensing revenue tied to its mRNA platform and pipeline.

Regeneron Pharmaceuticals, Inc. business model: Regeneron makes money from direct product sales and collaboration revenue. U.S. EYLEA and EYLEA HD sales, global Libtayo sales, rare-disease medicines, Sanofi profit-share economics for Dupixent, and Bayer EYLEA collaboration revenue are the main pillars.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Moderna, Inc. stack up against those of Regeneron Pharmaceuticals, Inc..

Moderna, Inc. competitive advantage: Moderna's advantage is a reusable mRNA platform, rapid design cycle, integrated manufacturing, regulatory experience, and a pipeline that can reuse chemistry, delivery, and clinical infrastructure.

Regeneron Pharmaceuticals, Inc. competitive advantage: Regeneron's advantage is its integrated discovery engine, VelociSuite technologies, founder-led scientific culture, manufacturing capabilities, and proven ability to move platform science into approved medicines.

Future prospects matter as much as current results. The growth strategies below explain how Moderna, Inc. and Regeneron Pharmaceuticals, Inc. each plan to expand from here.

Moderna, Inc. growth strategy: Moderna, Inc.'s growth strategy centers on this advantage: Moderna's advantage is a reusable mRNA platform, rapid design cycle, integrated manufacturing, regulatory experience, and a pipeline that can reuse chemistry, delivery, and clinical infrastructure.

Regeneron Pharmaceuticals, Inc. growth strategy: Regeneron's growth strategy centers on defending ophthalmology, scaling Dupixent economics, expanding Libtayo and oncology combinations, and selectively acquiring or partnering for new modalities.

A closer look at the financial trajectory of Moderna, Inc. and Regeneron Pharmaceuticals, Inc. rounds out the comparison.

Moderna, Inc.: Moderna, Inc. reported FY2025 revenue of $1.944B and a net loss of $2.822B.

Regeneron Pharmaceuticals, Inc.: Regeneron reported FY2025 revenue of about $14.34 billion and GAAP net income of about $4.50 billion. Dupixent global net sales recorded by Sanofi continued to grow, while the original EYLEA franchise faced tougher competition.